Moolec Science S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alejandro Antalich
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17 Boulevarrd F.W. Raiffeisen, Luxembourg Luxembourg 2411
- IPO Date
- Jan 3, 2023
- CIK
- 0001937737
- Website
- moolecscience.com
- Similar Companies
- Business
- Moolec Science S.A. is a science-based food ingredient company specializing in the development and commercialization of real animal proteins produced in plants using molecular farming technology. The company offers core products including Piggy Sooy™ and GLASO™, leveraging a proprietary soybean platform for sustainable animal protein production, alongside Mycofood™ under the Eternal® brand acquired through recent expansion. Moolec develops a range of protein ingredients and nutritional oils for applications in food, pet food, animal feed, and dietary supplements. Its services encompass research and development, contract development and manufacturing (CDMO), and regulatory consulting primarily through its expanded infrastructure under the Agrality® and Synbio Powerlabs® brands. Founded in 2008 and headquartered in the Cayman Islands with operations spanning global markets, Moolec focuses on delivering sustainable alternative proteins and ingredients with environmental benefits. In 2025, Moolec Science entered into a transformational business combination agreement with Bioceres Group Limited and related entities, creating a broader corporate structure positioning Moolec as the parent company with enhanced product portfolio diversification, cost efficiencies, and revenue growth opportunities. This combination integrates upstream technologies in regenerative agriculture, including biological inputs and climate-resilient seeds such as Rizobacter®, ProFarm®, and the HB4® trait, further advancing Moolec’s innovation footprint. The transaction also resulted in executive leadership changes and a strategic reorganization to support a diversified business model. Moolec continues to expand its molecular farming platform and product offerings consistent with its mission to innovate in sustainable food ingredient science and technology in the agriculture and biotech sectors.
Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
Moolec Science (MLEC) Stock Explodes 90% After GLA Update
Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions
Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
Moolec Science Announces Effectiveness of Share Consolidation
Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status
Moolec Receives Nasdaq Determination Letter
Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Why Is Moolec Science (MLEC) Stock Up 121% Today?
Why Is Moolec Science (MLEC) Stock Up 40% Today?
Moolec Science SA (MLEC) Q1 2024 Earnings Call Transcript